<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The active control trials, SPORTIF III and SPORTIF V, compared the direct thrombin inhibitor ximelagatran to <z:chebi fb="8" ids="10033">warfarin</z:chebi>, where each was given as a treatment to prevent <z:mpath ids='MPATH_118'>systemic embolism</z:mpath> and <z:hpo ids='HP_0001297'>stroke</z:hpo> in patients with <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Because <z:chebi fb="8" ids="10033">warfarin</z:chebi> has previously been compared to placebo in similar patients and ximelagatran has now been compared to <z:chebi fb="8" ids="10033">warfarin</z:chebi>, an indirect comparison between ximelagatran and placebo is possible (imputed placebo analysis) </plain></SENT>
<SENT sid="2" pm="."><plain>In this analysis, ximelagatran reduces the risk of <z:hpo ids='HP_0001297'>stroke</z:hpo> and <z:mpath ids='MPATH_118'>systemic embolism</z:mpath> by 66% (hazard ratio 0.338; 95% confidence interval [CI] 0.204-0.560) </plain></SENT>
<SENT sid="3" pm="."><plain>Ximelagatran preserves 102% (95% CI 72-132%) of the benefit of <z:chebi fb="8" ids="10033">warfarin</z:chebi> </plain></SENT>
<SENT sid="4" pm="."><plain>Based on these data, ximelagatran may be an effective alternative to <z:chebi fb="8" ids="10033">warfarin</z:chebi> for the prevention of <z:hpo ids='HP_0001297'>stroke</z:hpo> and <z:mpath ids='MPATH_118'>systemic embolism</z:mpath> in high-risk patients with <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo> </plain></SENT>
</text></document>